GSA Capital Partners’s Century Therapeutics IPSC Stock Holding History

GSA Capital Partners’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$174K	Sell	76,836 -256,363	-77%	-$539K	0.01%	1485
2025 Q4	$331K	Sell	333,199 -270,280	-45%	-$165K	0.03%	1110
2025 Q3	$301K	Buy	603,479 +136,873	+29%	+$73.8K	0.03%	1195
2025 Q2	$261K	Buy	+466,606	New	+$250K	0.02%	1349
2023 Q3	–	Sell	-20,472	Closed	-$65K	–	1694
2023 Q2	$65K	Buy	+20,472	New	+$66K	0.01%	1410

Other funds holding IPSC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

GSA Capital Partners's IPSC Position: Q1 2026 in Review

GSA Capital Partners reduced its Century Therapeutics (IPSC) stake by 77% in Q1 2026, selling an estimated $539K and leaving 76,836 shares worth $174K. The position accounts for 0.01% of the portfolio, ranked #1485.

GSA Capital Partners first reported a position in IPSC in Q2 2023 and has held it in 5 quarters since. The position peaked at $331K in Q4 2025. 72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

GSA Capital Partners held 76,836 shares of Century Therapeutics worth $174K as of Q1 2026.
GSA Capital Partners sold 256,363 Century Therapeutics shares in Q1 2026, an estimated $539K.
Century Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1485 holding.
GSA Capital Partners first reported a position in Century Therapeutics in Q2 2023 and has held it in 5 quarters since.
GSA Capital Partners's Century Therapeutics position peaked at $331K in Q4 2025.
72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.